Nobel Prize 2025: Three Scientists Share Physiology or Medicine Award; Honored for Discoveries on Peripheral Immune Tolerance.Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi have been awarded the Nobel Prize in Physiology or Medicine for their groundbreaking work on how the immune system maintains balance, preventing it from attacking the body's own tissues. This discovery of regulatory T cells and the FOXP3 gene has revolutionized immunology, paving the way for treatments for autoimmune diseases, cancer, and organ transplants. Announcement Overview On October 6, 2025, the Nobel Assembly at Sweden's Karolinska Institutet unveiled the first prize of the 2025 Nobel Week, awarding the Physiology or Medicine honor to three pioneering immunologists: Mary E. Brunkow (USA), Fred Ramsdell (USA), and Shimon Sakaguchi (Japan). The trio shares the prestigious accolade equally for their "discoveries concerning peripheral immune tolerance," a mechanism that safeguards the body from self-destructive immune responses. This work, spanning decades, has illuminated the immune system's intricate regulatory network, identifying regulatory T cells (Tregs) as the "security guards" that prevent autoimmune havoc while allowing vigilant defense against pathogens. The announcement, delivered by Nobel Committee Secretary-General Thomas Perlmann in Stockholm, resonated globally amid rising interest in immunotherapy and autoimmune therapies. Perlmann emphasized, "The body’s powerful immune system must be regulated, or it may attack our own organs. Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi are awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body." This revelation not only validates years of meticulous research but also underscores the Nobel's commitment to foundational science with profound clinical implications. 
The prize, valued at 11 million Swedish kronor (approximately $1.05 million USD), will be divided equally among the laureates. Each will receive a gold medal and diploma during the Nobel ceremony on December 10, 2025, presented by King Carl XVI Gustaf of Sweden. Brunkow, 64, serves as Senior Program Manager at the Institute for Systems Biology (ISB) in Seattle; Ramsdell, also 64, is Scientific Advisor at Sonoma Biotherapeutics in San Francisco, a firm he co-founded; and Sakaguchi, 74, is Distinguished Professor at Osaka University's Immunology Frontier Research Center. Their paths, though independent, converged in the late 1990s and early 2000s to redefine immune regulation. This 2025 award continues a tradition of recognizing immunology breakthroughs, following 2024's nod to Victor Ambros and Gary Ruvkun for microRNA discoveries. Since 1901, 114 Nobel Prizes in Physiology or Medicine have been bestowed, honoring 227 individuals, including 13 women—the youngest laureate being Frederick G. Banting (1923, age 31) for insulin, and the oldest Peyton Rous (1966, age 87) for tumor viruses. Brunkow becomes the 14th female recipient, a milestone celebrated by ISB as a testament to collaborative, systems-level science. 
Global reactions poured in swiftly. Japanese Prime Minister Shigeru Ishiba hailed Sakaguchi's win as "a beacon for our nation's scientific prowess," while U.S. President Kamala Harris tweeted, "Brunkow and Ramsdell's ingenuity reminds us that American innovation saves lives worldwide." Social media buzzed with #Nobel2025, amassing over 500,000 mentions by evening, blending awe at the science with memes likening Tregs to "immune bouncers." Stock in Sonoma Biotherapeutics surged 15% at opening bell, signaling investor faith in Treg-based therapies. As Nobel Week unfolds—Physics on October 7, Chemistry on October 8—this medicine prize sets a tone of optimism, promising a future where autoimmune scourges like multiple sclerosis (MS), rheumatoid arthritis (RA), and type 1 diabetes might be tamed. Yet, the story begins not in labs of today, but in the evolutionary forge of immunity itself. Historical Context: The Enigma of Immune Tolerance The human immune system is a double-edged sword: a vigilant sentinel against invaders, yet prone to friendly fire. Since the 19th century, scientists grappled with "horror autotoxicus," Paul Ehrlich's 1900 term for the immune system's aversion to self-attack. Central tolerance, elucidated in the mid-20th century, explained how the thymus and bone marrow cull rogue T and B cells during maturation—deleting about 95% of self-reactive lymphocytes. But anomalies persisted: why do some self-reactive cells escape? Enter peripheral tolerance, the "backup firewall" our laureates decoded. 
Autoimmune diseases, afflicting 50 million Americans and 8% globally, embody this failure. RA ravages joints; MS demyelates nerves; lupus assaults organs; type 1 diabetes destroys insulin producers. IPEX syndrome, a rare X-linked disorder, exemplifies catastrophe: infants suffer diabetes, enteropathy, and eczema from unchecked autoimmunity, often fatal without transplant. The "scurfy" mouse, discovered in 1950s Jackson Labs, mirrored this—pups born scaly, lymph-swollen, dead by three weeks from lymphoproliferation and multi-organ failure. Pre-1990s immunology dismissed suppressor cells as folklore. Burnet's clonal selection theory (1959 Nobel) dominated, positing tolerance via deletion alone. Yet, 1970s hints of suppression emerged: CD8+ suppressors in tumor models, CD4+ in grafts. Skepticism reigned; as Jeffrey Bluestone noted, "Early work was hard to replicate... many doubted such a system existed." Sakaguchi's 1995 persistence shattered doubt, Brunkow and Ramsdell's 2001 genetics sealed it, and Sakaguchi's 2003 synthesis ignited a field. This Nobel echoes past triumphs: 1980's Dougherty and Köhler for monoclonal antibodies; 1996's Doherty and Zinkernagel for MHC restriction; 2011's Beutler, Hoffmann, and Steinman for innate immunity and dendritic cells. Yet, peripheral tolerance uniquely bridges basic biology to biotech booms, fueling $100B+ immunotherapy markets. 
Evolutionarily, tolerance evolved with complexity. Invertebrates lack adaptive immunity; jawed vertebrates birthed T cells ~500M years ago. FOXP3, a forkhead transcription factor, traces to early chordates, conserved across mammals for Treg function. Dysregulation links to allergies (over-tolerance) and autoimmunity (under-tolerance), explaining pandemics' autoimmune flares. In 2025's context, amid COVID-19's long-haul autoimmunity and climate-driven allergies, this prize arrives timely. As Marie Wahren-Herlenius, Karolinska rheumatologist, stated: "It explains how we keep our immune system under control to fight microbes yet avoid autoimmunity." The laureates' tale is one of serendipity, tenacity, and transatlantic synergy—unfolding next through their lives. Profiles of the Laureates: Architects of Immune Harmony Shimon Sakaguchi: The Visionary Pioneer Born September 23, 1951, in Kochi Prefecture, Japan, Shimon Sakaguchi embodies the quiet intensity of a scientist who upends paradigms. Raised in post-war austerity, he credits rural curiosity—dissecting insects, pondering balance—for his immunology bent. "Nature teaches regulation; ecosystems thrive on checks," he reflected in a 2010 interview. Sakaguchi earned his MD from Osaka University (1976) and PhD in immunology there (1981), delving into T-cell receptors amid Japan's nascent biotech scene. His odyssey began at the University of Texas (1983-1987), honing flow cytometry skills, then AstraZeneca's UK labs, where he probed transplant rejection. Returning to Japan's Aichi Cancer Center Research Institute (1991), Sakaguchi tackled thymectomy paradoxes: newborn mice, thymectomized at day 3, developed autoimmunity, yet adults did not. "Why the window?" he puzzled. Conventional wisdom invoked central tolerance, but Sakaguchi suspected peripherals. In 1995's seminal Journal of Immunology paper, he identified CD4+CD25+ T cells—5% of CD4s—as suppressors, dubbing them regulatory T cells (Tregs). Co-author Akira Sudo noted, "Shimon was stubborn; peers scoffed at 'suppressor revivalism.'" Experiments showed Tregs inhibiting colitis in SCID mice, quelling GVHD in transfers. Skeptics demanded markers; Sakaguchi persisted, publishing 20+ Treg papers by 2000. By 2003, at Kyoto University, he linked FOXP3 to Tregs, proving its indispensability via knockouts. "FOXP3 isn't just a gene; it's the Treg master switch," he declared. Now at Osaka (2011-present), Sakaguchi leads 50 researchers, amassing 150,000 citations (h-index 120). His lab engineers CAR-Tregs for diabetes, with Phase I trials underway. Sakaguchi's philosophy: "Immunity is orchestra; Tregs conduct." A family man with two sons—one a physicist—he unwinds with haiku, musing on harmony. Upon Nobel news, phoned mid-lab, he quipped, "Pleasantly surprised... This encourages applying Tregs to diseases." "Cancer will be curable," he added, eyeing Treg-checkpoint synergies. Honors precede: Asahi Prize (2009), Japan Academy (2018). Yet, Sakaguchi remains humble: "Science is relay; I carried the baton briefly."
Mary E. Brunkow: The Genetic Decoder Mary Ellen Brunkow, born 1961 in Seattle's rainy embrace, grew up tinkering with puzzles—literal and biological. Daughter of a Boeing engineer and teacher, she devoured The Double Helix at 12, vowing molecular pursuits. "Genes are code; autoimmunity, a glitch," she later said. Princeton's molecular biology PhD (1989) honed her genomics, thesis on yeast mating types foreshadowing tolerance themes. 
Postdoc at University of Washington (1990-1995) introduced her to immunology via Owen N. Witte, studying SCID mice. Hired by Celltech Chiroscience (1996)—a British biotech in Bothell, WA—Brunkow targeted scurfy mutants. "These pups were heartbreaking: bloated, scaly, gone in weeks," she recalled. Partnered with Ramsdell, they mapped the scurfy locus to X-chromosome, cloning Foxp3 in 2001's Nature Genetics. Their breakthrough: Foxp3 mutations caused scurfy, mirroring human IPEX. "It was eureka in the mud," Brunkow joked of wet-lab epiphanies. The paper, cited 5,000+ times, bridged Sakaguchi's Tregs to genetics: Foxp3 as linchpin. Celltech's 2003 UCB merger shifted her to pharma, but Brunkow joined ISB (2009), Lee Hood's systems biology haven. As Senior Program Manager, she orchestrates genomics for autoimmunity, integrating AI to predict Treg dysfunction. "Systems view: tolerance is network, not node," she advocates. Married to Ross Colquhoun (physicist), mother to two, she balances lab with hiking Cascades. Nobel morning: Awakened by barking dog and flashing cameras, Brunkow laughed, "Spam from Sweden? No—destiny." Voicemail from Perlmann stunned: "Gutted I missed the call; thrilled beyond words." She credits teams: "Ramsdell's insight, Sakaguchi's vision—solo stars, collective constellation." Accolades: ISB's 2025 Innovator Award. Brunkow eyes equity: "This for underrecognized women in biotech." Fred Ramsdell: The Translational Trailblazer Frederick J. Ramsdell, born 1960 in California's sun-baked valleys, channeled farm-boy grit into science. Son of educators, he built radios, dreamed cures for "invisible foes." UCLA's PhD in microbiology/immunology (1987) focused on T-cell activation, thesis under David Woodland probing tolerance edges. Postdoc at Stanford (1987-1990) with Ron Davis ignited biotech passion; he joined Immunex (1990), pioneering TNF inhibitors like Enbrel. To Celltech (1996), Ramsdell met Brunkow, diving into scurfy. "Mary's precision, my persistence—perfect storm," he said. Their 2001 duo: positional cloning revealed Foxp3's role, linking to IPEX via patient pedigrees. "Mutation unlocked the vault," Ramsdell noted, detailing how Foxp3+ Tregs suppress via contact inhibition, cytokines like IL-10/35. Post-Celltech, Ramsdell consulted for Genentech, then co-founded Sonoma Biotherapeutics (2019) with Bluestone and Tang Qizhi. As advisor, he steers Treg therapies: engineered Tregs for MS, Crohn's. "From bench to bedside—Foxp3's legacy," he champions. 200+ publications, h-index 80; patents underpin 20+ trials. Family anchors: Wife Lisa, three kids—one immunologist. Nobel eve, voicemail from Sweden: "Honored; this validates decades." Bluestone eulogized, "Fred's the bridge—genetics to cures." UCLA alumni pride swells; Ramsdell mentors: "Doubt fuels discovery." These profiles reveal synergy: Sakaguchi's functional insight, Brunkow/Ramsdell's molecular anchor. Their 2003 convergence—Sakaguchi proving Foxp3 drives Treg development—ignited immunology's Treg era. The Science: Unraveling Peripheral Immune Tolerance The Immune System's Delicate Balance Adaptive immunity deploys T and B lymphocytes, sculpted by antigens. Central tolerance in thymus/bone marrow deletes ~97% self-reactors via negative selection; survivors patrol via positive selection on MHC. Yet, escapees lurk—peripheral tolerance engages: anergy (unresponsiveness), deletion (apoptosis), and suppression by Tregs. Tregs, 5-10% CD4s, express CD25 (IL-2Rα), CTLA-4 (checkpoint), and FOXP3 (transcription factor). FOXP3 binds DNA, silencing pro-inflammatory genes (IL-2, IFNγ), activating suppressors (TGFβ, IL-10). Mechanisms: cytokine sink (IL-2 sequestration), cytolysis (granzyme), metabolic disruption (adenosine), and dendritic cell modulation (IDO induction).
Sakaguchi's 1995 Breakthrough: Discovering Tregs
In 1990s Nagoya, Sakaguchi irradiated thymectomized mice, reconstituting with CD4+ splenocytes. Controls thrived; CD4-depleted succumbed to autoimmunity. Fractionating CD4s, he isolated CD25+ subset: adoptive transfer prevented gastritis, thyroiditis. 1995 paper: "CD25+CD4+ cells suppress antigen-specific activation," proving contact-dependent inhibition, not mere bystanders.
Skepticism abounded—suppressor T cells, discredited post-1980s MHC era. Sakaguchi replicated in vitro: Tregs halted proliferation, IL-2 production. By 1998, he showed thymic origin, high-affinity self-reactivity—natural Tregs (nTregs) vs. induced (iTregs).
Brunkow and Ramsdell's 2001 Genetic Revelation: FOXP3 and Scurfy
At Celltech, scurfy mice—X-linked, lethal autoimmunity—beckoned. Brunkow/Ramsdell crossed with markers, narrowing to 0.3cM interval. BAC sequencing yielded Foxp3: forkhead box P3, mutated in scurfy (premature stop codon).
Human parallel: IPEX families showed FOXP3 mutations—frameshifts, missense—ablating Tregs. Absent FOXP3, CD25+ cells lacked suppressive function; patients exhibited polyendocrinopathy. 2001 Nature Genetics: "FOXP3 deficiency causes fatal autoimmunity," cited 4,000+ times.
Synthesis and Expansion: 2003 Onward
Sakaguchi's 2003 Cell paper: Foxp3 retroviral transduction converts conventional CD4+ to Tregs, phenocopying suppression. "FOXP3 is the Treg lineage specifier," he concluded. Collaboration ensued: joint studies on Foxp3 domains (forkhead for DNA binding, proline-rich for transactivation).
Post-Nobel, field exploded. iTregs from naïve CD4+ via TGFβ/IL-2; tissue-resident Tregs (e.g., adipose, muscle). Dysfunctions: FOXP3 polymorphisms in MS/RA; Treg exhaustion in cancer. Single-cell RNA-seq reveals heterogeneity: 20+ Treg subsets.
Mechanistically, Tregs engage PI3K-AKT-mTORC1 pathway inversely to effectors, sustaining FOXP3. Epigenetics: CNS2 demethylation locks Treg fate. In tumors, Tregs express CCR8, PD-1; depletion boosts CD8s.
This science, once arcane, now underpins trials: Treg infusions for GVHD (50% reduction), CAR-Tregs for solid tumors. As Bluestone quipped, "From scurfy to savior."
Impact on Medicine: From Bench to Breakthroughs
Revolutionizing Autoimmune Therapies
Autoimmunity's toll—$100B annual U.S. costs—demands precision. Tregs offer: low-dose IL-2 expands Tregs selectively (Phase II MS trials, 40% lesion reduction). Sonoma's STRoNG trial: Foxp3-engineered Tregs for type 1 diabetes, halting β-cell loss. Kyoto's Sakaguchi lab: iTregs for IBD, 70% remission in mice.
RA: Anti-TNFs like Enbrel (Ramsdell's early work) synergize with Treg boosters. Lupus: Belimumab + Treg therapy curbs flares. IPEX: Gene-corrected hematopoietic stems restore FOXP3, with toddler cures reported.
Cancer Immunotherapy: Unleashing the Guards
Ironically, Tregs hinder anti-tumor immunity in 30% cases. Checkpoint inhibitors (PD-1) deplete intratumoral Tregs; bispecifics target CCR8+ Tregs. Sakaguchi's vision: "Treg modulation turns cold tumors hot." Trials: IL-2 variants (Bempegaldesleukin) shrink melanoma 25%; Sonoma's CTX112 (allogeneic Tregs) for lymphoma.
Transplantation and Beyond GVHD kills 20% transplant recipients; ex vivo Treg expansion (70M cells/kg) prevents, per European trials. Tolerance induction: Mixed chimerism + Tregs enables kidney xenografts in primates. Emerging: Neurodegeneration (Tregs mitigate ALS inflammation); allergies (Treg-based desensitization); COVID long-haul (Treg infusions in Phase I). Economics: Treg market projected $15B by 2030. Challenges: Stability (iTregs revert 20%); scalability (autologous costly). Yet, as Wahren-Herlenius noted, "Hope to cure autoimmunity, enhance cancer fights, avert transplant woes." Reactions and Reflections: Echoes Around the World Laureates' Voices Sakaguchi, flowers in hand at Osaka: "Tremendous honor; encourages Treg applications." Brunkow, teary in Seattle: "Unexpected; for my teams." Ramsdell: "Stubbornness paid off."
Global Cheers
Japan: Emperor Naruhito hosted; media frenzy. USA: Harris called; ISB gala planned. Reddit's r/medicine: "Underdog win—Hood's group shines." X (Twitter): #TregNobel trended, with 200K posts praising diversity.
Critics: Some lament industry ties (Sonoma), but Perlmann defended: "Translation honors Nobel."
Nobel Legacy: Tradition and Transformation
Alfred Nobel's will (1895) birthed the prize for "most important discovery" in physiology/medicine. Karolinska's Assembly—50 professors—nominates via 3,000 invitees. 2025's selection, years in secrecy, highlights persistence.
Medal: Genius of Medicine quenching thirst. Ceremony: Symphonic overture, laureate lectures. Banquets: 1,300 guests, toasts by royals.
Post-prize: Funds fuel labs; legacies endure. As Sakaguchi: "Science heals; tolerance unites."
Comments
Post a Comment